MyFinsight
Home
Blog
About
Contact
Download
Download image
Other Products
$229,654K
Baqsimi
$185,358K
Primatenemist
$108,669K
Epinephrine
$70,643K
Glucagon
$69,084K
Lidocaine
$56,479K
Revenues
$719,887K
(-1.65%↓ Y/Y)
Gross profit
$356,057K
(-4.76%↓ Y/Y)
Cost of revenues
$363,830K
(1.60%↑ Y/Y)
Income from operations
$140,403K
(-31.65%↓ Y/Y)
Total operating
expenses
$215,654K
(28.03%↑ Y/Y)
Income before income
taxes
$123,624K
(-34.85%↓ Y/Y)
Total non-operating
income (expenses), net
-$16,779K
(-7.18%↓ Y/Y)
Interest income
$8,679K
(-18.22%↓ Y/Y)
Other income
(expenses), net
$23K
(-99.44%↓ Y/Y)
General and
administrative
$85,925K
(51.49%↑ Y/Y)
Research and development
$85,844K
(16.14%↑ Y/Y)
Selling, distribution,
and marketing
$43,885K
(16.09%↑ Y/Y)
Income before equity in
losses of...
$98,094K
(-38.73%↓ Y/Y)
Income tax provision
$25,530K
(-13.96%↓ Y/Y)
Interest expense
$25,481K
(-16.02%↓ Y/Y)
Net income
$98,094K
(-38.51%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Amphastar Pharmaceuticals, Inc. (AMPH)
Amphastar Pharmaceuticals, Inc. (AMPH)